Optimal treatments for the metabolic syndrome.
Dario
D
Giugliano
Katherine
K
Esposito
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D000529:Complementary Therapies; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D004032:Diet; D015438:Health Behavior; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008019:Life Style; D024821:Metabolic Syndrome / Q000150:complications / Q000628:therapy*; D008687:Metformin / Q000627:therapeutic use; D009765:Obesity / Q000150:complications / Q000628:therapy*; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D010880:Piperidines; D011720:Pyrazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin; D000077285:Rimonabant